HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
Current Therapeutic Drugs Treating COVID-19
Therapeutic agents include antiviral agents like remdesivir, Hydroxychloroquine, Chloroquine, Lopinavir, Umifenovir, Favipiravir, and Oseltamivir, and supporting agents like Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others are used as therapeutic drugs in the treatment of COVID-19.
Committee Members
Miroslav Radenkovic
University of Belgrade, Serbia
A C Matin
Stanford University, United States
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Consolato M Sergi
University of Ottawa, Canada PDDS 2024 Speakers
Miroslav Radenkovic
University of Belgrade, Serbia
A C Matin
Stanford University, United States
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Andreas M Papas
Antares Health Products, United States
Consolato M Sergi
University of Ottawa, Canada
Thomas Ullrich
Novartis Biomedical Research, SwitzerlandSubmit your abstract Today
Title : Nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Novel nano drug platform for pharmacologically inducing therapeutic hypothermia (TH) after traumatic brain injury (TBI)
Jorge David Tovar Castro, University of Miami Miller School of Medicine, United States
Title : Global drug development - Trends, challenges and opportunities
Gurpreet Singh, IQVIA, United Kingdom
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Synthesis and properties of new unique heterocyclic systems: Pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]pyrimido[2,1-f][1,2,4]triazines
Anush, National Academy of Sciences of the Republic of Armenia, Armenia
Title : Development and evaluation of prolonged-release dutasteride transdermal delivery system
Shereen M. Assaf, Jordan University of Science and Technology, Jordan